CAM
ELEV

Cormorant Asset Management’s Elevation Oncology ELEV Stock Holding History

Cormorant Asset Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,952,032
Closed -$3.71M – 69
2023
Q1 		$3.71M Hold
1,952,032
– – 0.24% 53
2022
Q4 		$1.85M Hold
1,952,032
– – 0.12% 60
2022
Q3 		$2.21M Sell
1,952,032
-31,136
-2% -$39.2K 0.15% 59
2022
Q2 		$2.78M Buy
1,983,168
+3
+0% +$8 0.21% 59
2022
Q1 		$5M Hold
1,983,165
– – 0.38% 52
2021
Q4 		$11.9M Hold
1,983,165
– – 0.71% 38
2021
Q3 		$15.1M Hold
1,983,165
– – 0.62% 42
2021
Q2 		$25.6M Buy
+1,983,165
New +$24.5M 0.87% 32

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cormorant Asset Management's ELEV Position: Q2 2023 in Review

Cormorant Asset Management sold out of Elevation Oncology (ELEV) in Q2 2023, closing a stake of 1,952,032 shares — an estimated $3.71M sold.

Cormorant Asset Management first reported a position in ELEV in Q2 2021 and held it in 8 quarters. The position peaked at $25.6M in Q2 2021. 39 funds tracked by Wall St. Rank hold ELEV as of Q2 2023.

  • Cormorant Asset Management reported no remaining Elevation Oncology position as of Q2 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 1,952,032 Elevation Oncology shares in Q2 2023, an estimated $3.71M.
  • Cormorant Asset Management first reported a position in Elevation Oncology in Q2 2021 and held it in 8 quarters.
  • Cormorant Asset Management's Elevation Oncology position peaked at $25.6M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.